- Trials with a EudraCT protocol (744)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
744 result(s) found for: Breast Neoplasms.
Displaying page 1 of 38.
EudraCT Number: 2009-009418-42 | Sponsor Protocol Number: INT-07/09 | Start Date*: 2009-05-19 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy ... | |||||||||||||
Medical condition: Breast cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003752-38 | Sponsor Protocol Number: om 169 | Start Date*: 2003-12-09 | |||||||||||
Sponsor Name:OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer | |||||||||||||
Medical condition: advancer breast carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007089-12 | Sponsor Protocol Number: 2606 B | Start Date*: 2007-02-07 | |||||||||||
Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE | |||||||||||||
Full Title: Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women | |||||||||||||
Medical condition: Metastased breast cancer, first line treatment, for women with age>70 years old,Her2 positive | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000698-57 | Sponsor Protocol Number: MDV3100-11 | Start Date*: 2013-09-01 | |||||||||||
Sponsor Name:Medivation, Inc. | |||||||||||||
Full Title: A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer | |||||||||||||
Medical condition: Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001456-36 | Sponsor Protocol Number: EGF100151 | Start Date*: 2004-09-06 | |||||||||||
Sponsor Name:GLAXO SMITHKLINE | |||||||||||||
Full Title: A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer. | |||||||||||||
Medical condition: Solid tumor treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003220-52 | Sponsor Protocol Number: CC-486-BRSTM-001 | Start Date*: 2015-03-21 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Postmenopausal female subjects with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer, who have progressed on an aromatase inhibi... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004848-23 | Sponsor Protocol Number: 89/2006/O/Sper | Start Date*: 2006-09-12 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Sequential Oral Therapy (SOT trial) in elderly patients with metastatic breast cancer: a phase IV randomized trial | |||||||||||||
Medical condition: breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016842-22 | Sponsor Protocol Number: MK01 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:photonamic GmbH & Co. KG | |||||||||||||
Full Title: Evaluation of the suitability of PD L 506 for intraoperative visualisation of palpable and nonpalpable breast cancer tissue | |||||||||||||
Medical condition: Breast cancer; palpable and non-palpable tumours of the female breast. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005114-33 | Sponsor Protocol Number: s57283 | Start Date*: 2015-03-10 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Effectiveness of Botulinum Toxin Infiltration for treatment of upper limb dysfunctions after treatment for breast cancer | |||||||||||||
Medical condition: The aim of this study is to examine the effect of Botolinum Toxine infiltration in the pectoral muscle, in combination with an individual physical therapy programme, on pain and upper limb dysfunct... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002850-35 | Sponsor Protocol Number: GEICAM/2016-03 | Start Date*: 2017-11-08 | |||||||||||
Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | |||||||||||||
Full Title: “LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES”. | |||||||||||||
Medical condition: Patients with invasive breast cancer in early stages. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000276-38 | Sponsor Protocol Number: MIBIOTIMI | Start Date*: 2021-07-06 | |||||||||||
Sponsor Name:Álvaro Ruibal Morell | |||||||||||||
Full Title: Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002665-35 | Sponsor Protocol Number: 190619 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:Mikkel Holm Vendelbo | |||||||||||||
Full Title: 16α-18F-fluor-17β-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005184-42 | Sponsor Protocol Number: CLEE011A2412B | Start Date*: 2022-04-15 | ||||||||||||||||
Sponsor Name:NOVARTIS PHARMA AG | ||||||||||||||||||
Full Title: A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study | ||||||||||||||||||
Medical condition: HR+, HER2- advanced or metastatic breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) PT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003559-39 | Sponsor Protocol Number: ICO-A-2018-10 | Start Date*: 2018-12-11 | |||||||||||
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||
Full Title: multicentric Study , open, randomized, comparing the topical treatment by patch of capsaïcine with 8 % ( Qutenza) to the oral prégabaline treatment in the early treatment of the neuropathic pains a... | |||||||||||||
Medical condition: men and /or women older than 18 years with breast cancer for which a surgical operation was realized. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006025-27 | Sponsor Protocol Number: IEOS380/607 | Start Date*: 2008-11-10 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in adv... | |||||||||||||
Medical condition: advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004430-26 | Sponsor Protocol Number: 010207QM | Start Date*: 2015-06-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Queen Mary University of London | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: FEASIBILITY of IBIS 3. An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Late recurrence of hormone receptor positive breast cancer | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001943-21 | Sponsor Protocol Number: IFG-08-2019 | Start Date*: 2021-05-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Institut für Frauengesundheit GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: NeoOn – Neoadjuvant treatment of Ontruzant® (SB3) in patients with HER2-positive early breast cancer: An open-label, multicenter, phase IV study | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Female patients with early HER2positive breast cancer, neoadjuvantly treated. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004100-35 | Sponsor Protocol Number: GBG102-SASCIA | Start Date*: 2020-10-09 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treat... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) IE (Ongoing) ES (Ongoing) AT (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001587-19 | Sponsor Protocol Number: UHSM0315 | Start Date*: 2015-07-15 | |||||||||||||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | |||||||||||||||||||||||
Full Title: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk | |||||||||||||||||||||||
Medical condition: We seek to investigate the breast cancer risk reducing properties of ulipristal acetate | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008698-69 | Sponsor Protocol Number: CRAD001Y2301 | Start Date*: 2009-07-28 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metasta... | |||||||||||||
Medical condition: estrogen receptor positive locally advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) NL (Completed) FR (Completed) BE (Completed) GB (Completed) DE (Completed) SE (Completed) ES (Completed) HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.